Spanish Pharmaceutical Leader Ferrer Partners with Wellthy Therapeutics

New Delhi: Wellthy Therapeutics DTx solution has emerged global winner at Ferrer's 4 Future Innovation Challenge

The Ferrer 4 Future Innovation Challenge aims to enable more personalized, effective and responsive care to patients through a connected healthcare ecosystem facilitated by digital technologies. The challenge included showcasing 65 health technology companies across the globe, out of which Wellthy Therapeutics emerged as the global winner.

"At Ferrer, we are convinced that promoting innovation and digital health solutions is key to finding new ways of improving patients' clinical outcomes and quality of life. That is why we created Ferrer 4 Future, our first-ever open innovation program launched by the company, as an active step towards collaborating with technology innovators to develop digital solutions across the patient care value chain. We are delighted to announce Wellthy Therapeutics as the winner, where we have found the right fit in both their digital therapeutic platform and their team. We are very much looking forward to collaborating as we strive together towards a common goal of better patient outcomes and quality of life," said Gemma Estrada, Ferrer's Head of Digital Health & Technology.

Wellthy Therapeutics will leverage its strengths of delivering DTx-driven real-world outcomes for multiple conditions, across diverse cultures and languages, while Ferrer will leverage its commercialization capability, market access and patient connect in specific geographies, to combine forces and deliver better patient outcomes at scale.

"Personalized, real-time care for every patient is the future of healthcare, and real-world outcomes are the new gold standard. Digital therapeutics solve massive gaps in healthcare, from access and affordability of world-class care in out-of-pocket markets to delivering better health outcomes and value-based care in insurance reimbursed markets. Long-lasting, collaborative digital therapeutic partnerships with pharma allow for the creation of multi-modal therapeutics that deliver impact to all healthcare stakeholders. We look forward to a deeper collaboration with Ferrer as we march towards improving health outcomes and quality of life for patients globally," said Abhishek Shah, CEO & Co-Founder, Wellthy Therapeutics.

Wellthy Therapeutics' DTx solution aligns with the current Indian government's Make in India agenda, to create innovative, world-class solutions for healthcare that are locally effective and globally scalable.

With this win, Ferrer will work with Wellthy Therapeutics towards a commercial partnership, details of which are yet to be finalised.

Read also: Amgen, BeiGene collaborate to expand oncology presence in China